For inquiries relating to CytoDyn’s currently active Expanded Access Program (EAP) for patients with triple-negative breast cancer (TNBC): CytoDynEAP@wepclinical.com
For all other (eIND) requests: dai@cytodyn.com
Criteria to Pre-Approval Access of Leronlimab Outside a Clinical Trial:
https://d1io3yog0oux5.cloudfront.net/_d14136e...Policy.pdf
https://www.cytodyn.com/investors/investor-faqs